IMUX raises €26.7M Growth round

12 April 2019· Mannheim, Germany· manufacturing, energy, robotics, b2b, software_hardware

The funding was raised concurrently with Immunic's NASDAQ listing via a reverse merger to provide sufficient financing into the third quarter of 2020.

Investors

LeadLife Sciences Partners
Also participating
High-Tech GründerfondsBayern KapitalLifeCare PartnersOmega FundsIBG Beteiligungsgesellschaft Sachsen-AnhaltFund+

About IMUX

Stage
Growth
Headquarters
Mannheim, Germany
Founded
2020
Team Size
6–20
Sectors
manufacturingenergyroboticsb2bsoftware_hardware

Source: https://www.htgf.de/en/high-tech-gruenderfonds-portfolio-company-immunic-therapeutics-to-trade-on-nasdaq/